



FOR IMMEDIATE RELEASE

## Sun Pharma signs non-exclusive patent licensing agreement with Takeda for introducing Novel Gastrointestinal Drug, Voltapraz (Vonoprazan) in India

**Mumbai, India, June 21, 2024:** Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that it has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Limited (Takeda) to commercialise Vonoprazan tablets 10 mg, 20 mg in India under the brand name “Voltapraz”. Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders.

Under the terms of this agreement, Takeda has granted Sun Pharma non-exclusive patent licensing rights for the commercialization of Vonoprazan in India.

Commenting on the development, Kirti Ganorkar, CEO - India Business, Sun Pharma said, “Sun Pharma is a leader in Gastroenterology and we are excited to introduce Vonoprazan in India under non-exclusive patent license from Takeda. This partnership demonstrates our commitment to Gastrointestinal health by providing patients and healthcare practitioners with a novel treatment option to manage reflux esophagitis and other acid peptic disorders.”

Gastroesophageal Reflux Disease (GERD) is common in India irrespective of geographical or rural/urban location.<sup>i</sup> Prevalence of GERD in Indian population ranges from 5% to 28.5%. Risk factors for GERD include age, body mass index (BMI), non-vegetarian diet, tea/coffee intake, tobacco, and alcohol consumption.<sup>ii</sup>

In November 2023, Vonoprazan was approved by the US FDA for healing and maintenance of healing of all grades of Erosive esophagitis and relief of heartburn associated with Erosive esophagitis and in combination with amoxicillin and clarithromycin or amoxicillin alone for the treatment of Helicobacter pylori (H. pylori) infection in adults.<sup>iii</sup>

Vonoprazan was discovered and developed by Takeda. With a novel mechanism of action, Vonoprazan inhibits the binding of potassium ions to H<sup>+</sup>K<sup>+</sup>ATPase (proton pump) in gastric parietal cells in the stomach thereby it suppresses basal and stimulated gastric acid secretion.<sup>iii</sup> The drug is approved in India for treatment of adults with Reflux esophagitis and other acid peptic disorders.

---

<sup>i</sup> Bhatia S, Pareek KK, Kumar A, et al. API-ISG Consensus Guidelines for Management of Gastroesophageal Reflux Disease. J Assoc Physicians India. 2020 Oct;68(10):69-80

<sup>ii</sup> Rai S, Kulkarni A, Ghoshal UC. Prevalence and risk factors for gastroesophageal reflux disease in the Indian population: A meta-analysis and meta-regression study. Indian J Gastroenterol. 2021 Apr;40(2):209-219

<sup>iii</sup> Vonoprazan tablets Prescribing Information dated November 2023. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/215151s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215151s000lbl.pdf). Accessed on 07 June 2024

Sun Pharmaceutical Industries Limited  
SUN HOUSE, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



---

**Disclaimer:**

Statements in this “Document” describing the Company’s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

**About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050):**

Sun Pharma is the world’s leading specialty generics company with presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun’s high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company’s vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. For further information, please visit [www.sunpharma.com](http://www.sunpharma.com) and follow us on LinkedIn & X (Formerly Twitter).

**Contacts:**

**Investors:**

Dr. Abhishek Sharma  
Tel +91 22 4324 4324, Xtn 2929  
Tel Direct +91 22 4324 2929  
Mobile +91 98196 86016  
E mail [abhi.sharma@sunpharma.com](mailto:abhi.sharma@sunpharma.com)

**Media:**

Gaurav Chugh  
Tel +91 22 4324 4324, Xtn 5373  
Tel Direct +91 22 4324 5373  
Mobile +91 98104 71414  
E mail [gaurav.chugh@sunpharma.com](mailto:gaurav.chugh@sunpharma.com)